GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revolution Medicines Inc (FRA:42Z) » Definitions » Short-Term Debt & Capital Lease Obligation

Revolution Medicines (FRA:42Z) Short-Term Debt & Capital Lease Obligation : €12.01 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Revolution Medicines Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Revolution Medicines's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was €12.01 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Revolution Medicines's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was €112.26 Mil.


Revolution Medicines Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Revolution Medicines's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revolution Medicines Short-Term Debt & Capital Lease Obligation Chart

Revolution Medicines Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial 3.02 5.50 6.39 6.76 12.29

Revolution Medicines Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Short-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.52 7.74 7.57 12.29 12.01

Revolution Medicines Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Revolution Medicines Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Revolution Medicines's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Revolution Medicines Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revolution Medicines Inc (FRA:42Z) » Definitions » Short-Term Debt & Capital Lease Obligation
Traded in Other Exchanges
Address
700 Saginaw Drive, Redwood City, CA, USA, 94063
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Revolution Medicines Headlines

No Headlines